BIOMAT Database Logo BIOMAT Database Logo

A randomized trial comparing safety and efficacy of OKT3 and a monoclonal anti-interleukin-2 receptor antibody (BT563) in the prevention of acute rejection after heart transplantation. 1996

T van Gelder, and A H Balk, and F A Jonkman, and R Zietse, and P Zondervan, and C J Hesse, and L M Vaessen, and B Mochtar, and W Weimar
Department of Internal Medicine I, University Hospital Rotterdam, The Netherlands.

In a prospective randomized trial, BT563, a murine IgG, anti-interleukin-2 receptor antibody, was compared with OKT3 for use as an early rejection prophylaxis after heart transplantation. Patients received either BT563 (n=31) or OKT3 (n=29) during the first 7 days after transplantation; cyclosporine was started on day 3. Median follow-up was 34 months. A cytokine release syndrome occurred in the majority of patients of the OKT3-treated group but in none of the BT563 recipients. The mean duration of electrical stimulation of the heart in the BT563 group was longer than in the OKT3 group (5.1 vs. 2.1 days). In both groups, one patient required insertion of a permanent pacemaker. Freedom from acute rejection at 3 months was not significantly different between the two groups (BT563: 5/29, 17%; OKT3: 6/29, 21%). In the BT563 group, however, rejection tended to occur earlier after transplantation. There was no difference in the overall incidence of rejection. The incidence of infectious complications was evenly distributed in both groups. Malignancies occurred in two patients, both in the OKT3 group. In conclusion, the use of this anti-interleukin-2 receptor monoclonal antibody in heart transplant recipients is safe and devoid of the side effects that accompany the use of OKT3. OKT3 and BT563 result in a similar freedom from rejection at 3 and 12 months after heart transplantation.

UI MeSH Term Description Entries
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003141 Communicable Diseases An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host. Infectious Diseases,Communicable Disease,Disease, Communicable,Disease, Infectious,Diseases, Communicable,Diseases, Infectious,Infectious Disease
D005260 Female Females
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal

Related Publications

T van Gelder, and A H Balk, and F A Jonkman, and R Zietse, and P Zondervan, and C J Hesse, and L M Vaessen, and B Mochtar, and W Weimar
A double-blind, placebo-controlled study of monoclonal anti-interleukin-2 receptor antibody (BT563) administration to prevent acute rejection after kidney transplantation.
August 1995, Transplantation,
T van Gelder, and A H Balk, and F A Jonkman, and R Zietse, and P Zondervan, and C J Hesse, and L M Vaessen, and B Mochtar, and W Weimar
Monoclonal antibodies in prophylactic immunosuppression after liver transplantation. A randomized controlled trial comparing OKT3 and anti-IL-2 receptor monoclonal antibody LO-Tact-1.
March 1993, Transplantation,
T van Gelder, and A H Balk, and F A Jonkman, and R Zietse, and P Zondervan, and C J Hesse, and L M Vaessen, and B Mochtar, and W Weimar
Prevention of acute rejection episodes with an anti-interleukin 2 receptor monoclonal antibody. II. Results after a second kidney transplantation.
January 1994, Transplantation,
T van Gelder, and A H Balk, and F A Jonkman, and R Zietse, and P Zondervan, and C J Hesse, and L M Vaessen, and B Mochtar, and W Weimar
Efficacy of anti-interleukin-2 receptor antibody in reducing the incidence of acute rejection after renal transplantation.
January 2012, Nephro-urology monthly,
T van Gelder, and A H Balk, and F A Jonkman, and R Zietse, and P Zondervan, and C J Hesse, and L M Vaessen, and B Mochtar, and W Weimar
Prevention of acute rejection episodes with an anti-interleukin 2 receptor monoclonal antibody. I. Results after combined pancreas and kidney transplantation.
January 1994, Transplantation,
T van Gelder, and A H Balk, and F A Jonkman, and R Zietse, and P Zondervan, and C J Hesse, and L M Vaessen, and B Mochtar, and W Weimar
Efficacy of anti-interleukin-2 receptor antibody (daclizumab) in reducing the incidence of acute rejection after renal transplantation.
January 2012, Nephro-urology monthly,
T van Gelder, and A H Balk, and F A Jonkman, and R Zietse, and P Zondervan, and C J Hesse, and L M Vaessen, and B Mochtar, and W Weimar
Chronic rejection after orthotopic liver transplantation is increased under induction therapy with interleukin-2 receptor antibody BT563.
May 2001, Transplantation proceedings,
T van Gelder, and A H Balk, and F A Jonkman, and R Zietse, and P Zondervan, and C J Hesse, and L M Vaessen, and B Mochtar, and W Weimar
Influence of the anti-CD25 monoclonal antibody BT563 on clinical and biological rejection after orthotopic liver transplantation.
December 1996, Transplantation proceedings,
T van Gelder, and A H Balk, and F A Jonkman, and R Zietse, and P Zondervan, and C J Hesse, and L M Vaessen, and B Mochtar, and W Weimar
Anti-IL-2 receptor BT563 versus placebo: a randomized trial for induction therapy after liver transplantation.
August 1998, Transplantation proceedings,
T van Gelder, and A H Balk, and F A Jonkman, and R Zietse, and P Zondervan, and C J Hesse, and L M Vaessen, and B Mochtar, and W Weimar
Anti-rejection therapy in renal transplantation: Use of the monoclonal antibody OKT3.
January 1991, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
Copied contents to your clipboard!